Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study is intended for Chronic Lymphocytic Leukemia patients who have already undergone a
first or second treatment with drugs named bendamustine and rituximab. It will observe the
results of this treatment and evaluate its efficacy and side effects.